financetom
Business
financetom
/
Business
/
Saw strong good growth across all verticals except household insecticides: Godrej Consumer Products
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Saw strong good growth across all verticals except household insecticides: Godrej Consumer Products
Nov 6, 2020 6:03 AM

Godrej Consumer Products’ second quarter revenues were at Rs 2915 crore, EBITDA came in at Rs 673 crore, profits were also in line with analyst estimates.

“We had strong growth overall, 11 percent growth in India and 11 percent in our international markets with 19 percent EBITDA growth,” says Nisaba Godrej, Chairperson and MD of Godrej Consumer Products.

Talking about underperforming segments she said, “We were sort of disappointed with our household insecticides growth because it was very strong Q1 and we were expecting a double digit growth in this quarter.”

“We did get impacted by supply chain issues. Q2 and Q3 for household insecticides are more salient than Q1 and Q4 so we were not able to meet demand in some key SKUs,” she further added.

“Going forward we are definitely seeing tailwinds in categories like hygiene and household insecticides. Even in categories like hair colour and hair care sequentially improvement.”

To know more about the company's Q2 performance, watch the video.

(Edited by : Santosh Nair)

First Published:Nov 6, 2020 3:03 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer
BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer
Apr 23, 2024
09:19 AM EDT, 04/23/2024 (MT Newswires) -- BeiGene ( BGNE ) said Tuesday that tislelizumab has received approval from the European Commission to treat non-small cell lung cancer in three indications, including first- and second-line use. The approval was based on the company's three late-stage trials in the Rationale program that had 1,499 participants. All three trials met their primary...
Bio-Techne Says It Filed Patent Infringement Lawsuit Against Molecular Instruments in Europe
Bio-Techne Says It Filed Patent Infringement Lawsuit Against Molecular Instruments in Europe
Apr 23, 2024
09:16 AM EDT, 04/23/2024 (MT Newswires) -- Bio-Techne ( TECH ) said Tuesday it has filed a lawsuit against Molecular Instruments in the Unified Patent Court in Europe over the alleged infringement of its patented RNAscope ISH technology. The company claims that Molecular Instruments' HCR 3.0 technology infringes its European Patents 1,910,572 and 2,500,439. The lawsuit aims for damages and...
Addus HomeCare 'Disappointed' with Compensation Requirement in Medicaid Final Rule; Shares Tumble Pre-Bell
Addus HomeCare 'Disappointed' with Compensation Requirement in Medicaid Final Rule; Shares Tumble Pre-Bell
Apr 23, 2024
09:18 AM EDT, 04/23/2024 (MT Newswires) -- Addus HomeCare ( ADUS ) said Tuesday it was disappointed that the Department of Health and Human Services kept a high compensation requirement in its final rule for Medicaid services. Addus shares were down 7.4% in recent premarket activity. A provision from the initial version of the rule mandates that 80% of Medicaid...
Canadian competition bureau has major concerns about proposed Bunge-Viterra merger
Canadian competition bureau has major concerns about proposed Bunge-Viterra merger
Apr 23, 2024
OTTAWA, April 23 (Reuters) - Canada's Competition Bureau on Tuesday said it had identified major competition concerns around the proposed merger between U.S. grains merchant Bunge and Glencore ( GLCNF )-backed Viterra. In a statement, the bureau said the deal was likely to result in substantial anti-competitive effects and a significant loss of rivalry between Viterra and Bunge in agricultural...
Copyright 2023-2026 - www.financetom.com All Rights Reserved